PF-04971729 (Ertugliflozin): Selective SGLT2 Inhibitor for Diabetes Mellitus Research

Executive Summary: PF-04971729 (Ertugliflozin) is a potent, selective SGLT2 inhibitor with an IC₅₀ of 0.877 nM for SGLT2 and minimal activity against off-target transporters such as OCT2 (IC₅₀ 900 μM), supporting its use in renal glucose transport studies (Nikolaou et al., 2022). It exhibits rapid absorption in healthy humans (T_max ~1 h, 25 mg oral dose), moderate metabolic elimination, and high solubility in DMSO and ethanol but is insoluble in water (APExBIO). The compound has demonstrated robust selectivity and pharmacokinetics across cell-based and in vivo models (ArotinololCompounds.com). Clinical and preclinical studies confirm its efficacy in glucose reabsorption inhibition and safety in diabetes mellitus research. The chemical and handling properties of PF-04971729 enable reproducible experimental workflows in translational diabetes research.

Biological Rationale

SGLT2 is the primary transporter responsible for glucose reabsorption in the renal proximal tubule. Inhibition of SGLT2 decreases plasma glucose levels by promoting urinary glucose excretion, a mechanism validated in both clinical and preclinical diabetes models (Nikolaou et al., 2022). SGLT2 inhibitors, including Ertugliflozin, are recommended for type 2 diabetes mellitus due to their efficacy in reducing glycemia, body weight, and blood pressure. PF-04971729 (Ertugliflozin) specifically targets the SGLT2-mediated glucose transport pathway with high selectivity, minimizing off-target effects on other renal transporters such as SGLT1 and OCT2 (APExBIO). This selectivity is essential for dissecting the renal glucose transport mechanism in research settings (Miglitol.com), and extends the mechanistic understanding beyond previous reviews by focusing on high-fidelity transporter selectivity.

Mechanism of Action of PF-04971729 (Ertugliflozin)

PF-04971729 acts by binding and inhibiting SGLT2 on renal proximal tubule epithelial cells, blocking reabsorption of filtered glucose from the urinary filtrate. This inhibition results in increased urinary glucose excretion and reduction of blood glucose concentrations. In vivo, this leads to decreased plasma glucose and a compensatory increase in urinary glucose output, confirmed by both rodent and human pharmacodynamic studies (Nikolaou et al., 2022). The compound displays weak inhibition of OCT2-mediated [¹⁴C]metformin uptake (IC₅₀ 900 μM), demonstrating high specificity for SGLT2 versus other transporters (APExBIO). This high selectivity profile enables precise interrogation of SGLT2-mediated glucose transport, supporting both in vitro and in vivo study designs.

Evidence & Benchmarks

• PF-04971729 (Ertugliflozin) increases urinary glucose excretion in murine and human studies, confirming on-target SGLT2 inhibition (Nikolaou et al., 2022).
• The compound exhibits an IC₅₀ of 0.877 nM for SGLT2 and >900 μM for OCT2, indicating a selectivity index >10⁵ for SGLT2 over OCT2 (APExBIO).
• Pharmacokinetic studies show rapid oral absorption (T_max ~1 h, 25 mg oral dose) and 35.3% unchanged excretion in feces/urine in healthy humans (APExBIO).
• SGLT2 inhibition by Ertugliflozin does not correlate with cardioprotection at standard equivalent doses in non-diabetic mouse models, underscoring the specificity of its renal glucose effects (Nikolaou et al., 2022).
• The compound has high solubility in DMSO (≥50.8 mg/mL) and ethanol (≥51.5 mg/mL) but is insoluble in water, ensuring compatibility with standard laboratory solvents (APExBIO).
• PF-04971729 is validated in both cell-based and translational in vivo models, facilitating reproducibility in diabetes mellitus research workflows (SitagliptinSyn.com).

Applications, Limits & Misconceptions

PF-04971729 (Ertugliflozin) is primarily utilized for mechanistic studies of renal glucose transport, SGLT2 pathway interrogation, and translational diabetes mellitus research. It is suitable for in vitro transporter selectivity assays, in vivo glucose reabsorption modeling, and pharmacokinetic studies where high target specificity is required. Its robust selectivity profile supports the development of SGLT2-focused therapeutics and mechanistic modeling of renal glucose handling (ArotinololCompounds.com). This article extends previous overviews by detailing quantitative selectivity and handling properties relevant to experimental reproducibility.

Common Pitfalls or Misconceptions

• Not a direct SGLT1 inhibitor: PF-04971729 shows minimal activity against SGLT1, limiting its use in studies targeting intestinal glucose transport.
• Does not produce cardioprotection at standard doses in non-diabetic models: Unlike empagliflozin or dapagliflozin, Ertugliflozin did not reduce infarct size at stoichiometric doses in mouse models (Nikolaou et al., 2022).
• Not water-soluble: The compound is insoluble in water, requiring DMSO or ethanol for preparation and limiting direct use in aqueous systems (APExBIO).
• Research Use Only: PF-04971729 is not intended for clinical or diagnostic use in humans (APExBIO).
• Sensitivity to long-term solution storage: Solutions degrade over time; fresh preparations are recommended for optimal activity.

Workflow Integration & Parameters

PF-04971729, available as SKU A3715 from APExBIO, is supplied as a solid suitable for dissolution in DMSO or ethanol at concentrations ≥50 mg/mL. For in vitro assays, final DMSO concentrations should not exceed 0.1–0.5% (v/v) in cell culture. Storage at -20°C is recommended for solid material; solutions should be prepared fresh for each experiment to preserve activity. In vivo, oral gavage or dietary administration is standard, with T_max (1 h) and bioavailability confirmed in healthy human volunteers. Excretion data indicates 35.3% of the dose is eliminated unchanged, suggesting moderate metabolism. These parameters support robust, reproducible SGLT2-targeted workflows from cell-based assays to animal models (SitagliptinSyn.com), clarifying handling details beyond standard product datasheets.

Conclusion & Outlook

PF-04971729 (Ertugliflozin) is established as a highly selective, potent, and reliable oral SGLT2 inhibitor for diabetes mellitus and renal glucose transport studies. Its robust pharmacological profile, rapid absorption, and favorable selectivity minimize off-target effects and facilitate translational research. While not a direct SGLT1 inhibitor nor cardioprotective at standard doses in non-diabetic models, it remains an advanced tool for dissecting the SGLT2-mediated glucose transport pathway. For further details, refer to the PF-04971729 (Ertugliflozin) product page or recent comparative reviews (OlodaterolLabs.com), which this article updates by providing detailed selectivity and workflow guidelines for APExBIO's product.